Regenicin Stock Profit Margin
| RGIN Stock | USD 0.0001 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Regenicin's long-term financial health and intrinsic value.
Regenicin |
Regenicin Company Profit Margin Analysis
Regenicin's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Regenicin has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Regenicin Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regenicin's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Regenicin could also be used in its relative valuation, which is a method of valuing Regenicin by comparing valuation metrics of similar companies.Regenicin is currently under evaluation in profit margin category among its peers.
Regenicin Fundamentals
| Return On Asset | -37.38 | |||
| Current Valuation | 659.26 K | |||
| Shares Outstanding | 153.48 M | |||
| Shares Owned By Insiders | 18.15 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | (9.70) X | |||
| EBITDA | (655.96 K) | |||
| Net Income | (639.26 K) | |||
| Cash And Equivalents | 2.24 K | |||
| Total Debt | 629.92 K | |||
| Debt To Equity | 0.34 % | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (27.29 K) | |||
| Earnings Per Share | (0) X | |||
| Beta | -1.79 | |||
| Market Capitalization | 214.88 K | |||
| Total Asset | 15.49 K | |||
| Retained Earnings | (11.8 M) | |||
| Working Capital | (1.53 M) | |||
| Current Asset | 293 K | |||
| Current Liabilities | 1.83 M | |||
| Net Asset | 15.49 K |
About Regenicin Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regenicin's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regenicin using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regenicin based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Regenicin Pink Sheet
Regenicin financial ratios help investors to determine whether Regenicin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Regenicin with respect to the benefits of owning Regenicin security.